PharmacoEconomics & Outcomes News

, Volume 770, Issue 1, pp 13–13 | Cite as

Erlotinib reduces AE rate and healthcare costs versus afatinib

Clinical study
  • 9 Downloads

Reference

  1. Isla D, et al. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. ClinicoEconomics and Outcomes Research 2017: 31-38, No. 9, 30 Dec 2016. Available from: URL: https://doi.org/10.2147/CEOR.S121093 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Personalised recommendations